Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.44 USD
−29.07 M USD
0.00 USD
43.76 M
About Trevi Therapeutics, Inc.
Sector
Industry
CEO
Jennifer L. Good
Website
Headquarters
New Haven
Founded
2011
FIGI
BBG003QGQRB9
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TRVI is 2.91 USD — it has increased by 6.59% in the past 24 hours. Watch Trevi Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Trevi Therapeutics, Inc. stocks are traded under the ticker TRVI.
TRVI stock has risen by 0.34% compared to the previous week, the month change is a −9.35% fall, over the last year Trevi Therapeutics, Inc. has showed a 125.58% increase.
We've gathered analysts' opinions on Trevi Therapeutics, Inc. future price: according to them, TRVI price has a max estimate of 21.00 USD and a min estimate of 6.00 USD. Watch TRVI chart and read a more detailed Trevi Therapeutics, Inc. stock forecast: see what analysts think of Trevi Therapeutics, Inc. and suggest that you do with its stocks.
TRVI reached its all-time high on Jun 3, 2019 with the price of 10.62 USD, and its all-time low was 0.46 USD and was reached on Feb 22, 2022. View more price dynamics on TRVI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
TRVI stock is 10.15% volatile and has beta coefficient of 0.60. Track Trevi Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Trevi Therapeutics, Inc. there?
Today Trevi Therapeutics, Inc. has the market capitalization of 223.68 M, it has decreased by −0.73% over the last week.
Yes, you can track Trevi Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Trevi Therapeutics, Inc. is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
TRVI earnings for the last quarter are −0.13 USD per share, whereas the estimation was −0.12 USD resulting in a −8.75% surprise. The estimated earnings for the next quarter are −0.12 USD per share. See more details about Trevi Therapeutics, Inc. earnings.
Trevi Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
TRVI net income for the last quarter is −13.24 M USD, while the quarter before that showed −12.35 M USD of net income which accounts for −7.21% change. Track more Trevi Therapeutics, Inc. financial stats to get the full picture.
No, TRVI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 25.00 employees. See our rating of the largest employees — is Trevi Therapeutics, Inc. on this list?
Like other stocks, TRVI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Trevi Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Trevi Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Trevi Therapeutics, Inc. stock shows the buy signal. See more of Trevi Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.